Varonis Systems Inc

VRNS is consolidating in a tight range between $44.00 support and $45.15 resistance following a strong Stage 2 advance. Price is tightly tracking above rising 9-, 20-, and 50-day EMAs, but no active patterns are present to signal clear direction. The medium- and long-term uptrends remain intact, supported by the 200-day SMA well below current levels. Patient entry near the EMA cluster or upon a decisive breakout is warranted, avoiding premature purchases on chop.

• ↑SaaS ARR up 25% YoY to $598.1M, fueling subscription momentum
• ↑New Atlas Interceptor and data monitoring tools driving product traction
• ↓On-premise federal renewal rates fell, undermining ARR stability